Prognostic analysis of the expression of CD86 in cancer tissues showed that CD86 could inhibit tumor progression and prolong the overall survival time of patients for 3 years (P = 0.04), which further verified the effect of M1 macrophages in inhibiting tumor growth. This evidence concerns the gene CD86 and cancer.